Bioventus Inc (BVS)

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItMay 22, 2026 10:31 AM
PR Newswire (US) Issued on behalf of Conexeu Sciences Inc.Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bioventus Inc. (NASDAQ: BVS), Mesoblast Limited (NASDAQ: MESO)KEY TAKEAWAYSA fresh Nasdaq debut. Conexeu Sciences Inc. (Nasdaq: CNXU) began trading on May 21, 2026, marking the public-market entry of a Reno-based regenerative tissue platform company targeting wound care, breast reconstruction, and aesthetic medicine — three of the largest unmet-need categories in healthcare today.One platform, multiple markets. Conexeu's proprietary CXU™ extracellular matrix platform is designed to scale across multiple addressable markets without reformulation — a structural advantage rarely available to early-stage regenerative medicine companies.A new approach to mastectomy reconstruction. Conexeu's B.R.E.A.S.T.™ matrix is a 3D-bioprinted scaffold designed to support the body's own tissue regeneration, not to remain as a permanent implant — a potential paradigm shift for the more than 100,000 U.S. women who undergo mastectomies annually.Clean intellectual property. Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing freedom to expand into new indications.Regulatory pathway in motion. The company is targeting a 510(k) submission in early 2027 for its initial indication, subject to regulatory review.NEW YORK, May 22, 2026 /PRNewswire/ -- USA News Group News Commentary — Wall Street's regenerative medicine bench just got one name deeper. On May 21, 2026, Conexeu Sciences Inc. (Nasdaq: CNXU) commenced trading on the Nasdaq, formally entering public markets as a preclinical-stage company built around a single, scalable bioregenerative platform that the company calls CXU™. Chairman Jeff Sharpe framed the listing-day milestone as a positioning move for the long arc of what's coming. "Today marks an important milestone in Conexeu's evolution as we enter the public markets during an important period of advancement across regenerative medicine, biomaterials science, and tissue restoration," he said. The investor pitch, in short: a platform that can address several multi-billion-dollar end markets through a single underlying technology — rather than the more typical biotech model of one molecule, one indication.The Platform
CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost through injury, aging, and GLP-1-associated tissue-related weight loss. The first product expression, Ten Minute Tissue™, is a CXU-based injectable ECM that remains fluid at room temperature and transitions to a stable gel in situ at body temperature within approximately ten minutes. In preclinical studies, it has demonstrated enhanced healing dynamics, organized scaffold formation, and a favorable (low) inflammatory profile.The second high-profile expression of the same platform is B.R.E.A.S.T.™ — a 3D-bioprinted regenerative breast matrix that gradually resorbs as the patient's own tissue remodels and replaces it over time. It is investigational, has not been submitted to or reviewed by the FDA, and is limited by U.S. federal law to investigational use.The platform is grounded in more than a decade of university preclinical research and protected by issued patents across the U.S., E.U., Japan, and Australia, with additional filings pending.The Market Context
CNXU enters a public-market peer set that is showing genuine commercial momentum. A handful of recent earnings prints and corporate updates illustrate why the category is drawing capital.Integra LifeSciences Holdings Corporation (NASDAQ: IART) delivered one of the most compelling regenerative-medicine quarters of the year. The company reported Q1 2026 results that significantly beat expectations, with adjusted EPS of $0.54 against a forecast of $0.40 — an EPS surprise of 35%. The market response was emphatic. Both revenue and adjusted EPS came in above guidance, driven by product demand and supply chain improvements, with strong performance in Tissue Reconstruction propelled by notable growth from Integra Skin and DuraSorb as well as a robust launch for PriMatrix. The stock surged into the print, with IART up about 24% on the day.Evolus, Inc. (NASDAQ: EOLS) has been building a category-defining presence in performance beauty. On May 11, 2026, Evolus announced commercial launch of Estyme in Europe, and on May 14, 2026, the company completed a key NUCEIVA safety study, easing risk for aesthetic toxin investors. Analyst sentiment has remained constructive — BTIG sticks to a Buy rating on Evolus. The product mix of Jeuveau, the neurotoxin franchise, and Evolysse, a collection of injectable hyaluronic acid gels, places it squarely inside the same aesthetic-medicine market that Conexeu's GLP-1 contouring strategy targets.Bioventus Inc. (NASDAQ: BVS) rounds out the active-healing comp set. The company reported Q1 2026 EPS of $0.15, which was 50% higher than the projected $0.10, and revenue also exceeded forecasts, coming in at $132.1 million compared to the anticipated $129.86 million. Management raised the FY26 adjusted EPS view to 75c-79c from 73c-77c. Bioventus's portfolio across pain treatments, restorative therapies, and surgical solutions sits alongside Conexeu's wound care positioning as one of the larger commercial proof points in active healing.Mesoblast Limited (NASDAQ: MESO) highlights the upside narrative still embedded in the regenerative-medicine field. Mesoblast is a regenerative medicine company built around mesenchymal lineage cells, with Ryoncil already on the market for steroid-refractory acute graft versus host disease and a pipeline extending into chronic heart failure and chronic low back pain. On April 6, 2026, Mesoblast announced Ryoncil® net sales of US$30.3 million for the quarter ended March 31, 2026, with cumulative first-year launch revenue approaching US$100 million. Average analyst target prices have set up meaningful potential upside from current trading levels.Why The Listing Matters
For Conexeu, going public unlocks the next phase of capital formation needed to advance its platform across multiple product lines and toward its planned 510(k) submission in early 2027. H.C. Wainwright & Co. served as the exclusive financial advisor to the Company on the listing.For investors, the broader pattern is harder to miss. Tissue regeneration, advanced wound care, aesthetic injectables, and 3D-bioprinted scaffolds are no longer adjacent niches — they are converging into a single, multi-billion-dollar therapeutic adjacency. Conexeu's value proposition rides on whether its CXU™ platform can deliver across more than one of those categories with the same underlying material. That platform thesis is the structural difference between CNXU and most other preclinical-stage biotech debuts.About Conexeu Sciences Inc.
Conexeu Sciences is a preclinical-stage regenerative tissue platform company. Its patented bioregenerative extracellular matrix (ECM) platform, CXU™, is built on a single structural principle: one formula, one device, designed to scale across multiple addressable markets without reformulation. The Company is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.Contact:
USA News Group
info @therooster-2873Source
1. https://www.newsfilecorp.com/release/298401/Conexeu-Sciences-Commences-Trading-on-Nasdaq-Under-Ticker-Symbol-CNXU — primary release dated May 21, 2026 (Conexeu Sciences Inc.).Disclaimer: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed by USA News Group on behalf of MIQ. MIQ has been paid a fee for Conexeu Sciences Inc. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of Conexeu Sciences Inc. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. The owner/operator of MIQ currently owns shares of Conexeu Sciences Inc. that were purchased in the open market and reserves the right to buy and sell, and will buy and sell shares of Conexeu Sciences Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of Conexeu Sciences Inc. by CDMG; this is a digital media distribution.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg  View original content to download multimedia:https://www.prnewswire.com/news-releases/regenerative-medicines-newest-public-company-is-building-tissue-not-replacing-it-302780212.htmlSOURCE USA News Group Original: Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

BVS 10Q 11/5

BVS anew 52 week high

BVS new 52=high

BVS new 52 week high

BVS under $10

Durolane like it .. older news ..Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Source: GlobeNewswire Inc.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.
OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.

“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

$BVS - Bioventus GAAP EPS of -$0.07 beats by $0.18, revenue of $129.45M beats by $11.07M https://t.co/IGk1Zy2r5X— Seeking Alpha Market Currents (@MarketCurrents) May 7, 2024

BVS under $5